HSF1 and pachyonychia congenita: In summary, our results suggest that HSF1 can serve as a risk-grade indicator and prognostic biomarker for PC and that combination therapy consisting of targeting HSF1 and ferroptosis inducers might represent a novel therapeutic approach for PC in future.